

## SUPPLEMENTARY MATERIAL

### Quantitative and Qualitative Role of Antagonistic Heterogeneity in Genetics of Blood Lipids

Alexander M. Kulminski<sup>1</sup>, Yury Loika<sup>1</sup>, Alireza Nazarian<sup>1</sup>, and Irina Culminskaya<sup>1</sup>

<sup>1</sup>Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC 27708-0408, USA.

Supplementary materials include one Text, one Figure and four Tables.

<b>1. Supplementary Text</b>	<b>2</b>
<b>1.1. Supplementary Acknowledgment Text</b>	<b>2</b>
<b>2. Supplementary Figures</b>	<b>4</b>
<b>2.1. Supplementary Figure 1</b>	<b>4</b>
Pair-wise correlation coefficients between lipid traits	
<b>3. Supplementary Tables</b>	<b>5</b>
<b>3.1. Supplementary Table 1</b>	<b>5</b>
Basic characteristics of cohorts included in the analyses and the available sample sizes	
<b>3.2. Supplementary Table 2</b>	<b>6</b>
Replicated genetic associations with lipid traits with at most minor effect of antagonistic genetic heterogeneity	
<b>3.3. Supplementary Table 3</b>	<b>11</b>
Replicated genetic associations with lipid traits substantially strengthened by dissecting antagonistic genetic hetero	
<b>3.4. Supplementary Table 4</b>	<b>16</b>
Extended table showing new genetic associations with lipid traits and the associations strongly affected by antagonistic genetic heterogeneity	

## **1. Supplementary Text**

### **Supplementary Acknowledgment Text.**

The Framingham Heart Study (FHS) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the FHS and does not necessarily reflect the opinions or views of the FHS, Boston University, or NHLBI. Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL-64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University.

The Atherosclerosis Risk in Communities Study (ARIC) is carried out as a collaborative study supported by the NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for GENEVA was provided by the National Human Genome Research Institute grant U01HG004402 (E. Boerwinkle).

The Cardiovascular Health Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and N01-HC-85239; grant numbers U01 HL080295 and U01 HL130014 from the National Heart, Lung, and Blood Institute (NHLBI), and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at <https://chs-nhlbi.org/pi>. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African-American cohort was supported in part by HL085251. DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

Multi-Ethnic Study of Atherosclerosis (MESA) and the MESA SHARe project are conducted and supported by the NHLBI in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and CTSA UL1-RR-024156. Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278. This manuscript was not prepared in collaboration with MESA investigators and does not necessarily reflect the opinions or views of MESA, or the NHLBI.

The Health and Retirement Study (HRS) genetic data is sponsored by the Genetics Resource with HRS April 21, 2010, version G Page 5 of 7 National Institute on Aging (grant numbers U01AG009740, RC2AG036495, and RC4AG039029) and was conducted by the University of Michigan. This manuscript was not prepared in collaboration with HRS investigators and does not necessarily reflect the opinions or views of HRS.


The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A listing of WHI investigators can be found at <http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf>.

The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (N01-HC95095 & N01-HC48047), University of Minnesota (N01-HC48048), Northwestern University (N01-HC48049), and Kaiser Foundation Research Institute (N01-HC48050). This manuscript was not approved by CARDIA. The opinions and conclusions contained in this publication are solely those of the authors, and are not endorsed by CARDIA or the NHLBI and should not be assumed to reflect the opinions or conclusions of either. Genotyping for the CARDIA GENEVA cohort was supported by grant U01 HG004729 from the National Human Genome Research Institute.

## 2. Supplementary Figures

### Supplementary Figure 1. Pair-wise correlation coefficients between lipid traits.

Correlation coefficients,  $r$ , are representatively given as in the Atherosclerosis Risk in Communities Study. Phenotypes include: high-density lipoprotein cholesterol (HDL-C); low-density lipoprotein cholesterol (LDL-C); total cholesterol (TC); and triglycerides (TG).



### 3. Supplementary Tables

**Supplementary Table 1. Basic characteristics of cohorts included in the analyses and the available sample sizes.**

<b>Cohort</b>	<b>Sample size</b>	<b>Age (SD), years</b>	<b>BC range</b>	<b>Gender, female (%)</b>	<b>HDL-C (SD), [mg/dl]</b>	<b>LDL-C (SD), [mg/dl]</b>	<b>TC (SD), [mg/dl]</b>	<b>TG (SD), [mg/dl]</b>
<b>ARIC</b>	9,593	54.33 (6.55)	1921-1944	53.01	50.50 (17.15)	137.63 (36.63)	214.91 (39.37)	137.48 (89.47)
<b>CARDIA</b>	1,666	25.55 (6.21)	1950-1965	53.42	52.06 (14.04)	108.61 (31.64)	176.42 (34.12)	78.66 (67.64)
<b>CHS</b>	3,218	72.39 (5.82)	1890-1925	60.20	55.12 (15.10)	130.54 (34.98)	212.83 (39.01)	140.36 (82.18)
<b>FHS_C1</b>	875	53.66 (13.65)	1885-1920	60.12	53.42 (15.77)	189.79 (44.02)	242.55 (46.01)	125.99 (98.49)
<b>FHS_C2</b>	3,298	35.13 (13.63)	1910-1960	52.21	56.91 (15.62)	117.37 (35.66)	190.24 (39.41)	73.94 (102.79)
<b>FHS_C3</b>	3,883	40.01 (9.34)	1930-1980	53.23	61.01 (16.08)	104.78 (32.09)	185.30 (35.42)	97.61 (90.44)
<b>HRS</b>	4,021	72.47 (8.77)	1916-1975	59.95	58.99 (19.73)	99.28 (35.34)	186.35 (42.07)	135.93 (63.95)
<b>MESA</b>	2,364	64.25 (10.30)	1917-1957	51.40	53.26 (15.44)	113.44 (32.32)	192.65 (36.61)	130.34 (80.65)
<b>WHI</b>	984	64.28 (7.99)	1914-1943	100.00	57.00 (14.93)	140.58 (35.46)	228.03 (38.30)	154.64 (82.62)

**Cohorts:** Atherosclerosis Risk in Communities Study (ARIC); Coronary Artery Risk Development in Young Adults (CARDIA); Cardiovascular Health Study (CHS); Framingham Heart Study (FHS) original cohort (FHS\_C1); FHS Offspring (FHS\_C2); FHS 3<sup>rd</sup> generation cohort (FHS\_C3), Health and Retirement Study (HRS); the Multi-Ethnic Study of Atherosclerosis (MESA), and the Genomics and Randomized Trials Network (GARNET) sub-study of the Women’s Health Initiative (WHI).

**Quantitative markers (lipids):** high-density lipoprotein cholesterol (HDL-C); low-density lipoprotein cholesterol (LDL-C); total cholesterol (TC); and triglycerides (TG).

BC denotes birth cohorts; SD denotes standard deviation.

**Supplementary Table 2. Replicated genetic associations with lipid traits with at most minor effect of antagonistic genetic heterogeneity.**

SNP info								
ID	SNP	Chr	Position	Locus	Gene	Function	EA	EAF
1	rs16827981	1	23,435,538	ASAP3	LUZP1	UTR-5	a	0.18
2	rs693668	1	55,521,109	PCSK9	PCSK9	intron	g	0.35
3	rs10889332	1	62,950,858	ANGPTL3	DOCK7	intron, UTR-3	t	0.33
4	rs629301	1	109,818,306	SORT1	CELSR2	UTR-3	g	0.22
5	rs629301	1	109,818,306	SORT1	CELSR2	UTR-3	g	0.22
6	rs4846914	1	230,295,691	GALNT2	GALNT2	intron	g	0.40
7	rs556107	1	234,853,059	IRF2BP2		intergenic	c	0.47
8	rs7575840	2	21,273,490	APOB		intergenic	t	0.33
9	rs7575840	2	21,273,490	APOB		intergenic	t	0.33
10	rs41360247	2	44,073,656	ABCG5/8	ABCG8	intron,nearGene-5	c	0.07
11	rs41360247	2	44,073,656	ABCG5/8	ABCG8	intron,nearGene-5	c	0.07
12	rs7371606	2	136,806,774	RAB3GAP1		intergenic	g	0.34
13	rs3846663	5	74,655,726	HMGCR	HMGCR	intron	t	0.38
14	rs3846663	5	74,655,726	HMGCR	HMGCR	intron	t	0.38
15	rs9391858	6	32,341,398	HLA	C6orf10, LOC101929163	intron,nearGene-5	g	0.14
16	rs1564348	6	160,578,860	LPA	SLC22A1	intron	c	0.16
17	rs1564348	6	160,578,860	LPA	SLC22A1	intron	c	0.16
18	rs4466298	7	17,992,014	SNX13		intergenic	a	0.45
19	rs17145738	7	72,982,874	MLXIPL	TBL2	nearGene-3	t	0.12
20	rs13230111	7	130,437,124	KLF14	LOC105375508	intron	g	0.48
21	rs1461729	8	9,187,242	PPP1R3B	LOC157273	intron	a	0.09
22	rs17482753	8	19,832,646	LPL		intron	t	0.10
23	rs17482753	8	19,832,646	LPL		intron	t	0.10
24	rs17321515	8	126,486,409	TRIB1		intergenic	g	0.47
25	rs17321515	8	126,486,409	TRIB1		intergenic	g	0.47
26	rs17321515	8	126,486,409	TRIB1		intergenic	g	0.47
27	rs10761779	10	65,274,927	JMJD1C	JMJD1C	intron	g	0.49
28	rs174547	11	61,570,783	FADS1-2-3	FADS1	intron	c	0.33
29	rs651821	11	116,662,579	APOA1	APOA5	UTR-5	c	0.07
30	rs9989419	16	56,985,139	CETP		intergenic	a	0.39
31	rs10438978	18	47,158,186	LIPG	LOC105372112	intron	t	0.17
32	rs1122608	19	11,163,601	LDLR	SMARCA4	intron	t	0.25
33	rs1122608	19	11,163,601	LDLR	SMARCA4	intron	t	0.25
34	rs10401969	19	19,407,718	CILP2	SUGP1	intron	c	0.07
35	rs10401969	19	19,407,718	CILP2	SUGP1	intron	c	0.07
36	rs10401969	19	19,407,718	CILP2	SUGP1	intron	c	0.07
37	rs4420638	19	45,422,946	APOE	APOC1	nearGene-3	g	0.16
38	rs4420638	19	45,422,946	APOE	APOC1	nearGene-3	g	0.16
39	rs753381	20	39,797,465	TOP1	PLCG1	missense	t	0.45
40	rs7679	20	44,576,502	PLTP	PCIF1	UTR-3	c	0.19

Supplementary Table 2. (continue)

SNP info	Current Study														
		Trait_1_unconditional							Trait_1_conditional						
ID	Trait pair	Trait_1	Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TC	TC	2.13	0.39	5.55E-08	+++++++	11	3.40E-01	2.14	0.39	3.56E-08	0.19	+++++++	6	3.90E-01
2	HDL-LDL	LDL-C	-1.57	0.29	8.92E-08	-----+	22	2.51E-01	-1.60	0.29	3.59E-08	0.40	-----+	23	2.39E-01
3	HDL-TC	TC	-2.44	0.32	3.11E-14	-----+	55	2.47E-02	-2.38	0.32	8.84E-14	-0.45	-----+	50	4.17E-02
4	LDL-TG	LDL-C	-6.03	0.34	1.85E-72	-----	4	4.03E-01	-6.03	0.33	3.10E-73	0.78	-----	6	3.85E-01
5	HDL-TC	TC	-5.80	0.36	2.13E-57	-----	0	5.95E-01	-5.88	0.36	4.22E-60	2.70	-----	0	5.33E-01
6	HDL-LDL	HDL-C	-0.70	0.13	3.69E-08	---?---	8	3.65E-01	-0.70	0.13	3.81E-08	-0.01	---?---	0	4.39E-01
7	HDL-TC	TC	-1.71	0.30	1.70E-08	-----	0	5.81E-01	-1.65	0.30	4.18E-08	-0.39	-----	0	6.35E-01
8	HDL-LDL	LDL-C	3.26	0.30	3.91E-28	+++++++	31	1.70E-01	3.22	0.29	2.61E-28	0.18	+++++++	24	2.28E-01
9	HDL-TC	TC	3.19	0.32	2.59E-23	+++++++	25	2.20E-01	3.23	0.32	2.80E-24	0.97	+++++++	20	2.67E-01
10	LDL-TG	LDL-C	-3.56	0.55	1.25E-10	-----?	0	9.53E-01	-3.60	0.55	5.51E-11	0.36	-----?	0	9.47E-01
11	TC-TG	TC	-3.63	0.61	1.93E-09	-----?	0	7.05E-01	-3.68	0.58	2.42E-10	0.90	-----?	0	9.50E-01
12	HDL-TC	TC	1.95	0.34	7.05E-09	+++++??	52	5.35E-02	1.92	0.33	1.00E-08	-0.15	+++++??	47	7.77E-02
13	HDL-LDL	LDL-C	2.51	0.32	1.88E-15	++++?+++	24	2.44E-01	2.63	0.31	3.16E-17	1.78	++++?+++	23	2.52E-01
14	TC-TG	TC	2.79	0.34	1.75E-16	++++?+++	0	6.33E-01	2.80	0.32	3.28E-18	1.73	++++?+++	0	5.24E-01
15	HDL-TC	TC	2.40	0.43	3.18E-08	+++++++	19	2.78E-01	2.36	0.43	3.60E-08	-0.05	+++++++	23	2.39E-01
16	LDL-TG	LDL-C	2.32	0.39	2.42E-09	+++++++	0	6.50E-01	2.27	0.39	4.14E-09	-0.23	+++++++	0	4.84E-01
17	HDL-TC	TC	2.40	0.42	1.41E-08	+++++++	0	7.58E-01	2.45	0.42	4.87E-09	0.46	+++++++	4	8.41E-01
18	HDL-LDL	HDL-C	-0.70	0.12	5.59E-09	-----	0	8.04E-01	-0.69	0.12	8.48E-09	-0.18	-----	0	5.65E-01
19	TC-TG	TG	-10.97	0.91	1.71E-33	-----	0	4.36E-01	-10.38	0.87	6.72E-33	-0.59	+-----	12	3.32E-01
20	HDL-LDL	HDL-C	0.67	0.12	4.33E-08	+++++++?	0	5.20E-01	0.67	0.12	3.24E-08	0.13	+++++++?	0	4.42E-01
21	TC-TG	TC	-3.46	0.51	1.75E-11	-----	0	4.97E-01	-3.45	0.49	1.96E-12	0.95	-----	0	9.47E-01
22	HDL-LDL	HDL-C	2.59	0.20	5.12E-38	+++++++	50	4.06E-02	2.54	0.20	1.75E-37	-0.53	+++++++	41	9.62E-02
23	TC-TG	TG	-12.82	0.96	7.69E-41	-----	55	2.32E-02	-12.95	0.91	9.73E-46	4.90	-----	62	6.94E-03
24	HDL-LDL	LDL-C	-1.95	0.28	4.63E-12	-----	0	9.50E-01	-1.79	0.28	1.15E-10	-1.40	-----	0	9.80E-01
25	HDL-TC	TC	-2.44	0.30	1.09E-15	-----	0	9.77E-01	-2.60	0.30	7.75E-18	2.15	-----	0	9.88E-01
26	LDL-TG	TG	-6.12	0.67	3.66E-20	-----	43	8.24E-02	-4.61	0.55	7.79E-17	-3.33	-----	0	7.01E-01
27	TC-TG	TG	-3.85	0.67	1.09E-08	-----	0	7.60E-01	-3.71	0.64	8.12E-09	0.13	-----	0	9.33E-01
28	HDL-LDL	HDL-C	-0.99	0.13	9.49E-15	+-----	65	3.77E-03	-1.08	0.13	1.93E-17	2.69	+-----	64	5.00E-03
29	TC-TG	TG	21.70	1.59	1.22E-42	+++++++	8	2.38E-01	18.46	1.52	4.87E-34	-8.60	+++++++	30	1.75E-01
30	HDL-TG	HDL-C	-2.04	0.16	1.73E-39	----?--	0	5.80E-01	-1.91	0.14	2.75E-40	0.80	----?--	0	5.59E-01
31	HDL-TG	HDL-C	-1.41	0.16	8.12E-19	-----?	21	2.66E-01	-1.43	0.15	2.72E-22	3.48	-----?	0	4.72E-01
32	LDL-TG	LDL-C	-2.71	0.35	1.24E-14	---?+?	46	8.48E-02	-2.71	0.35	6.79E-15	0.26	---?+?	42	1.13E-01
33	TC-TG	TC	-2.51	0.38	3.14E-11	---?+?	13	3.29E-01	-2.52	0.36	2.44E-12	1.11	---?+?	24	2.44E-01
34	HDL-TC	TC	-4.53	0.58	4.52E-15	-----	41	9.18E-02	-4.52	0.57	2.37E-15	0.28	-----	46	6.04E-02
35	HDL-TG	TG	-8.63	1.13	1.91E-14	-----	0	4.58E-01	-8.08	1.02	2.01E-15	0.98	-----	11	3.48E-01
36	HDL-LDL	LDL-C	-2.95	0.53	2.78E-08	+-----	42	9.03E-02	-2.81	0.53	8.97E-08	-0.51	+-----	32	1.65E-01
37	HDL-LDL	LDL-C	5.02	0.41	5.32E-35	+++++?+?	60	2.14E-02	4.72	0.40	8.25E-32	-3.19	+++++?+?	59	2.39E-02
38	HDL-TC	TC	5.01	0.44	2.51E-30	+++++?+?	66	7.39E-03	5.24	0.43	1.55E-33	3.21	+++++?+?	62	1.47E-02
39	HDL-LDL	LDL-C	-1.51	0.28	7.27E-08	-----+	37	1.22E-01	-1.54	0.28	3.06E-08	0.38	-----+	36	1.31E-01
40	HDL-TC	HDL-C	-1.03	0.15	6.59E-12	-----	0	9.41E-01	-1.03	0.15	5.79E-12	0.06	-----	0	9.33E-01

Supplementary Table 2. (continue)

SNP info	Current Study														
	Trait pair	Trait 2 conditional							Trait 2 conditional						
ID	Trait pair	Trait 2	Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TC	HDL-C	0.09	0.16	5.85E-01	+-----+	0	8.17E-01	-0.02	0.16	9.03E-01	-0.19	-----+	0	7.92E-01
2	HDL-LDL	HDL-C	-0.01	0.13	9.45E-01	+++++++	0	9.23E-01	-0.12	0.13	3.61E-01	0.42	-+++++	0	9.15E-01
3	HDL-TC	HDL-C	-0.26	0.13	3.74E-02	-----+	13	3.27E-01	-0.18	0.13	1.52E-01	-0.61	-----+	9	3.64E-01
4	LDL-TG	TG	-0.88	0.78	2.62E-01	+++++--	24	2.26E-01	0.97	0.67	1.51E-01	0.24	+++++++	50	4.40E-02
5	HDL-TC	HDL-C	0.43	0.15	3.58E-03	++++++-	36	1.30E-01	0.65	0.15	7.57E-06	2.67	++++++-	42	8.59E-02
6	HDL-LDL	LDL-C	-0.38	0.30	2.07E-01	+++?+--	22	2.59E-01	-0.65	0.30	3.06E-02	0.83	+++?+--	18	2.89E-01
7	HDL-TC	HDL-C	-0.01	0.12	9.54E-01	+++++--	0	4.68E-01	0.07	0.12	5.80E-01	0.22	+++++--	0	6.77E-01
8	HDL-LDL	HDL-C	-0.12	0.13	3.30E-01	+++++++	0	6.03E-01	0.08	0.13	5.43E-01	-0.22	+++++++	0	5.23E-01
9	HDL-TC	HDL-C	-0.12	0.13	3.30E-01	+++++++	0	6.03E-01	-0.25	0.13	4.97E-02	0.82	+++++++	0	4.36E-01
10	LDL-TG	TG	-0.22	1.34	8.70E-01	-----?	0	5.05E-01	0.95	1.13	3.97E-01	0.34	-----?	0	5.07E-01
11	TC-TG	TG	-0.22	1.34	8.70E-01	-----?	0	5.05E-01	1.95	1.28	1.29E-01	0.83	-----?	23	2.51E-01
12	HDL-TC	HDL-C	0.13	0.13	3.13E-01	+++++??	27	2.21E-01	0.04	0.13	7.83E-01	-0.40	+++++??	15	3.12E-01
13	HDL-LDL	HDL-C	0.29	0.13	2.90E-02	++++?+++?	0	9.31E-01	0.50	0.13	1.31E-04	2.34	++++?+++?	0	9.82E-01
14	TC-TG	TG	-0.35	0.74	6.42E-01	+++?+--	0	7.81E-01	-2.12	0.71	2.69E-03	2.38	+++?+--	0	8.58E-01
15	HDL-TC	HDL-C	0.16	0.17	3.59E-01	+++++++	28	1.97E-01	0.05	0.17	7.68E-01	-0.33	+++++++	32	1.60E-01
16	LDL-TG	TG	1.50	0.92	1.05E-01	+++++++	26	2.10E-01	0.60	0.75	4.21E-01	-0.60	+++++++	50	4.13E-02
17	HDL-TC	HDL-C	-0.29	0.16	7.03E-02	-----+	0	5.64E-01	-0.39	0.16	1.48E-02	0.68	-----+	0	7.37E-01
18	HDL-LDL	LDL-C	-0.03	0.28	9.24E-01	-----+	42	8.72E-02	-0.22	0.28	4.25E-01	0.34	-----+	48	5.45E-02
19	TC-TG	TC	-1.03	0.46	2.55E-02	+++++--	33	1.52E-01	0.38	0.44	3.96E-01	-1.19	+++++--	47	5.69E-02
20	HDL-LDL	LDL-C	-0.13	0.28	6.39E-01	+++++--?	0	5.24E-01	0.10	0.28	7.32E-01	-0.06	+++++--?	0	5.44E-01
21	TC-TG	TG	0.21	1.12	8.53E-01	+++++--	46	6.37E-02	2.21	1.07	3.91E-02	1.34	+++++--	26	2.17E-01
22	HDL-LDL	LDL-C	0.31	0.46	4.98E-01	+++++--	0	6.27E-01	1.13	0.45	1.27E-02	1.59	+++++--	0	8.20E-01
23	TC-TG	TC	0.55	0.50	2.69E-01	+++++--	14	3.15E-01	2.27	0.48	2.00E-06	5.13	+++++--	0	5.04E-01
24	HDL-LDL	HDL-C	0.56	0.12	3.16E-06	+++++++	0	9.83E-01	0.38	0.12	1.68E-03	-2.73	+++++++	0	9.49E-01
25	HDL-TC	HDL-C	0.56	0.12	3.16E-06	+++++++	0	9.83E-01	0.66	0.12	4.04E-08	1.89	+++++++	0	9.61E-01
26	LDL-TG	LDL-C	-1.95	0.28	4.63E-12	-----	0	9.50E-01	-1.66	0.28	3.14E-09	-2.83	-----	0	9.83E-01
27	TC-TG	TC	-0.29	0.30	3.45E-01	+++++--	30	1.83E-01	0.18	0.29	5.42E-01	-0.20	+++++--	22	2.50E-01
28	HDL-LDL	LDL-C	-1.72	0.30	5.96E-09	-----	45	6.93E-02	-2.03	0.29	4.20E-12	3.15	-----	54	2.64E-02
29	TC-TG	TC	4.48	0.62	3.38E-13	+++++++	31	1.74E-01	1.66	0.59	5.07E-03	-10.18	+++++++	33	1.58E-01
30	HDL-TG	TG	2.29	0.84	6.60E-03	++++?++	0	4.90E-01	-1.99	0.77	9.37E-03	-0.15	++++?++	29	2.10E-01
31	HDL-TG	TG	-0.35	0.86	6.87E-01	+++++--?	24	2.38E-01	-3.17	0.79	6.10E-05	4.05	+++++--?	3	4.06E-01
32	LDL-TG	TG	-0.39	0.81	6.33E-01	++++?+?	43	1.01E-01	0.90	0.69	1.91E-01	0.52	++++?+?	0	6.39E-01
33	TC-TG	TG	-0.39	0.81	6.33E-01	++++?+?	43	1.01E-01	1.21	0.77	1.16E-01	0.74	++++?+?	52	5.22E-02
34	HDL-TC	HDL-C	0.35	0.23	1.31E-01	+++++++	0	8.94E-01	0.50	0.23	2.89E-02	0.66	+++++++	0	9.37E-01
35	HDL-TG	HDL-C	0.35	0.23	1.31E-01	+++++++	0	8.94E-01	-0.29	0.21	1.75E-01	-0.12	+++++++	0	6.06E-01
36	HDL-LDL	HDL-C	0.35	0.23	1.31E-01	+++++++	0	8.94E-01	0.10	0.23	6.66E-01	-0.71	+++++++	0	9.57E-01
37	HDL-LDL	HDL-C	-0.97	0.18	8.13E-08	---?+??	0	4.66E-01	-0.54	0.18	2.82E-03	-4.54	---?+??	25	2.50E-01
38	HDL-TC	HDL-C	-0.97	0.18	8.13E-08	---?+??	0	4.66E-01	-1.15	0.17	3.40E-11	3.38	---?+??	0	8.04E-01
39	HDL-LDL	HDL-C	-0.01	0.12	9.58E-01	+++++--	0	4.30E-01	-0.14	0.12	2.49E-01	0.58	+++++--	5	3.97E-01
40	HDL-TC	TC	-0.24	0.39	5.45E-01	+++++--	3	4.12E-01	0.06	0.39	8.74E-01	-0.21	+++++--	5	3.91E-01



**Supplementary Table 2.** (continue)

SNP info	Prior Studies		
	Lead SNP	LD, %	Effect sign
1	rs1077514	0.4	??-?
2	rs2479409	4.6	?++?
3	rs2131925	100	?---
4	rs629301	100	?--?
5	rs629301	100	?--?
6	rs4846914	100	-??+
7	rs514230	94	?--?
8	rs1367117	82.8	?++?
9	rs1367117	82.8	?++?
10	rs4299376	4.1	?++?
11	rs4299376	4.1	?++?
12	rs7570971	34.7	?++?
13	rs12916	93.9	?++?
14	rs12916	93.9	?++?
15	rs3177928	96.6	?++?
16	rs1564348	100	?++?
17	rs1564348	100	?++?
18	rs4142995	13.8	-???
19	rs17145738	100	+??-
20	rs4731702	100	+???
21	rs9987289	73.4	---?
22	rs12678919	100	+??-
23	rs12678919	100	+??-
24	rs2954029	98	+---
25	rs2954029	98	+---
26	rs2954029	98	+---
27	rs10761731	85	???-
28	rs174546	100	---+
29	rs964184	51.9	+---
30	rs3764261	23.2	+--+
31	rs7241918	96.4	-?-?
32	rs6511720	20.2	?--?
33	rs6511720	20.2	?--?
34	rs10401969	100	?---
35	rs10401969	100	?---
36	rs10401969	100	?---
37	rs4420638	100	-++?
38	rs4420638	100	-++?
39	rs6029526	72.3	?++?
40	rs6065906	100	-??+

**SNP info**

ID is a sequential single nucleotide polymorphism (SNP) number; Chr = chromosome; Position is position in base pairs; Locus denotes locus name as used in previous studies; EA denotes minor allele used as an effect allele in an additive genetic model; EAF = EA frequency.

**Current Study**

Trait pair = a pair of lipid traits examined.

Beta denotes effect size and direction of the genetic association; SE = standard error.

Direction shows the signs of associations in each of the included cohorts ordered as CHS, FHS\_C1, FHS\_C2, FHS\_C3, HRS, ARIC, CARDIA, MESA, and WHI, where “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects, respectively, and “?” indicates the lack of estimate.

$I^2$  is coefficient of heterogeneity in the meta-analysis; HetPVal is heterogeneity  $p$ -value in the meta-analysis.

dlogP is the difference of the log-base-10-transformed  $p$ -values in the unconditional and conditional analyses.

**Prior Studies**

Lead SNP is leading SNP identified in previous studies; LD = linkage disequilibrium between the lead SNPs and SNPs identified in the current study; Effect sign shows directions of genome-wide significant associations of the lead SNPs with HDL-C, LDL-C, TC, and TG reported in previous studies. Symbols “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects attained GW significance (i.e.,  $p \leq p_{GW}$ ), respectively, and “?” indicates associations, which did not attain GW significance level (i.e.,  $p > p_{GW}$ ).

**Supplementary Table 3. Replicated genetic associations with lipid traits substantially strengthened by dissecting antagonistic genetic heterogeneity.**

SNP info								
ID	SNP	Chr	Position	Locus	Gene	Function	EA	EAF
1	rs4350231	1	62,922,660	ANGPTL3	DOCK7	intron	a	0.33
2	rs4846914	1	230,295,691	GALNT2	GALNT2	intron	g	0.40
3	rs780094	2	27,741,237	GCKR	GCKR	intron	t	0.42
4	rs780094	2	27,741,237	GCKR	GCKR	intron	t	0.42
5	rs6716987	2	136,963,494	RAB3GAP1		intergenic	a	0.34
6	rs1461729	8	9,187,242	PPP1R3B	LOC157273	intron	a	0.09
7	rs1461729	8	9,187,242	PPP1R3B	LOC157273	intron	a	0.09
8	rs17321515	8	126,486,409	TRIB1		intergenic	g	0.47
9	rs12686004	9	107,653,426	ABCA1	ABCA1	intron	a	0.12
10	rs1051006	11	47,306,585	LRP4	MADD	missense	a	0.17
11	rs174547	11	61,570,783	FADS1-2-3	FADS1	intron	c	0.33
12	rs174547	11	61,570,783	FADS1-2-3	FADS1	intron	c	0.33
13	rs174547	11	61,570,783	FADS1-2-3	FADS1	intron	c	0.33
14	rs651821	11	116,662,579	APOA1	APOA5	UTR-5	c	0.07
15	rs651821	11	116,662,579	APOA1	APOA5	UTR-5	c	0.07
16	rs7120963	11	116,830,261	APOA1	SIK3	intron	t	0.36
17	rs261332	15	58,727,325	LIPC	LIPC	intron	a	0.20
18	rs261332	15	58,727,325	LIPC	LIPC	intron	a	0.20
19	rs289715	16	57,008,508	CETP	CETP	intron	a	0.12
20	rs10468274	16	67,922,342	LCAT	NRN1L	intron	a	0.17
21	rs16996185	19	19,720,788	CILP2	PBX4	intron	g	0.08
22	rs3208856	19	45,296,806	APOE	CBLC	missense	t	0.03
23	rs4420638	19	45,422,946	APOE	APOC1	nearGene-3	g	0.16

Supplementary Table 3. (continue)

SNP info	Current Study														
		Trait_1_unconditional							Trait_1_conditional						
ID	Trait pair	Trait_1	Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TG	TG	-3.82	0.68	1.94E-08	-----	33	1.51E-01	-4.35	0.62	2.07E-12	3.97	-----	11	3.45E-01
2	TC-TG	TG	3.57	0.75	1.75E-06	++++?++++	31	1.79E-01	3.89	0.71	4.95E-08	1.55	++++?++++	36	1.45E-01
3	HDL-TG	TG	7.72	0.68	3.96E-30	+++++++	44	7.55E-02	7.73	0.61	2.18E-36	6.26	+++++++	47	5.97E-02
4	LDL-TC	TC	2.32	0.31	3.29E-14	+++++++	0	9.46E-01	1.45	0.13	9.93E-30	15.52	+++++++	4	4.02E-01
5	TC-TG	TC	1.73	0.34	3.63E-07	+++++??	6	3.81E-01	1.87	0.32	7.86E-09	1.66	+++++??	19	2.87E-01
6	HDL-LDL	HDL-C	-1.19	0.20	4.02E-09	-----+	20	2.64E-01	-1.34	0.20	2.42E-11	2.22	-----	27	2.07E-01
7	HDL-LDL	LDL-C	-2.20	0.47	3.43E-06	-----	0	9.85E-01	-2.61	0.47	2.71E-08	2.10	-----	0	9.37E-01
8	HDL-TC	HDL-C	0.56	0.12	3.16E-06	+++++++	0	9.83E-01	0.66	0.12	4.04E-08	1.89	+++++++	0	9.61E-01
9	HDL-LDL	HDL-C	-0.88	0.18	1.04E-06	-+-----	9	3.58E-01	-1.01	0.18	1.71E-08	1.78	-+-----	9	3.58E-01
10	HDL-TG	HDL-C	0.80	0.16	7.86E-07	+++++++	17	2.91E-01	0.82	0.15	4.23E-08	1.27	+++++++	31	1.74E-01
11	TC-TG	TC	-2.18	0.32	1.61E-11	-----	3	4.07E-01	-2.55	0.31	1.14E-16	5.15	-+-----	49	4.66E-02
12	TC-TG	TG	3.42	0.71	1.53E-06	+++++++	43	8.08E-02	4.66	0.68	7.59E-12	5.30	+++++++	60	1.13E-02
13	HDL-LDL	LDL-C	-1.72	0.30	5.96E-09	---+-----	45	6.93E-02	-2.03	0.29	4.20E-12	3.15	---+-----	54	2.64E-02
14	HDL-TC	HDL-C	-1.64	0.24	4.13E-12	-----	31	1.71E-01	-1.80	0.24	1.92E-14	2.33	-----	24	2.32E-01
15	HDL-TC	TC	4.48	0.62	3.38E-13	+++++++	31	1.74E-01	4.91	0.61	9.22E-16	2.56	+++++++	8	4.38E-01
16	HDL-TG	TG	5.46	0.72	2.65E-14	+++++++	42	8.85E-02	6.20	0.65	1.82E-21	7.16	+++++++	0	5.04E-01
17	LDL-TC	TC	2.39	0.38	2.31E-10	+++++++	0	7.95E-01	2.27	0.16	8.12E-46	35.45	+++++++	0	7.39E-01
18	HDL-TG	HDL-C	1.58	0.15	2.73E-25	+++++++	34	1.49E-01	1.81	0.14	3.71E-38	12.87	+++++++	35	1.35E-01
19	HDL-TG	HDL-C	1.92	0.20	7.47E-23	+++++++	0	7.28E-01	1.94	0.18	3.60E-27	4.32	+++++++	0	6.92E-01
20	HDL-TG	HDL-C	0.94	0.16	5.51E-09	+++++++	45	7.14E-02	0.98	0.15	4.27E-11	2.11	+++++++	45	7.13E-02
21	HDL-TG	TG	-7.76	1.19	6.58E-11	-----?--	16	3.03E-01	-7.71	1.07	4.56E-13	2.16	-----?--	32	1.75E-01
22	TC-TG	TC	-4.71	0.92	2.74E-07	-----?-?	70	3.20E-03	-5.48	0.87	3.01E-10	2.96	-----?-?	68	4.46E-03
23	HDL-TC	HDL-C	-0.97	0.18	8.13E-08	----?-?-?	0	4.66E-01	-1.15	0.17	3.40E-11	3.38	----?-?-?	0	8.04E-01

Supplementary Table 3. (continue)

SNP info	Current Study														
		Trait 2 conditional							Trait 2 conditional						
ID	Trait pair	Trait 2	Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TC	HDL-C	-0.31	0.13	1.35E-02	-----+--	7	3.78E-01	-0.57	0.12	8.07E-07	6.09	-----	0	7.21E-01
2	HDL-LDL	TC	-0.40	0.33	2.17E-01	+++?--+	20	2.73E-01	-0.90	0.31	3.75E-03	1.76	+++?---	35	1.46E-01
3	HDL-TC	HDL-C	0.00	0.12	9.83E-01	++++-----	13	3.26E-01	0.58	0.11	2.05E-07	6.68	+++++++--	0	5.69E-01
4	LDL-TG	LDL-C	0.92	0.28	1.12E-03	+++++++	0	9.72E-01	-1.05	0.12	2.84E-19	15.60	-----	22	2.45E-01
5	HDL-TC	TG	-1.02	0.72	1.59E-01	-+-----??	0	7.74E-01	-2.13	0.69	2.09E-03	1.88	-+-----??	0	7.01E-01
6	HDL-LDL	LDL-C	-2.20	0.47	3.43E-06	-----	0	9.85E-01	-2.61	0.47	2.71E-08	2.10	-----	0	9.37E-01
7	HDL-TC	HDL-C	-1.19	0.20	4.02E-09	-----+--	20	2.64E-01	-1.34	0.20	2.42E-11	2.22	-----	27	2.07E-01
8	HDL-LDL	TC	-2.44	0.30	1.09E-15	-----	0	9.77E-01	-2.60	0.30	7.75E-18	2.15	-----	0	9.88E-01
9	HDL-TC	LDL-C	-1.32	0.43	1.91E-03	-+-----+	0	4.45E-01	-1.60	0.42	1.38E-04	1.14	-+-----+	21	2.52E-01
10	LDL-TG	TG	0.01	0.92	9.90E-01	-+-----+	0	9.40E-01	1.98	0.84	1.84E-02	1.73	+++++++--	0	9.43E-01
11	TC-TG	TG	3.42	0.71	1.53E-06	+++++++	43	8.08E-02	4.66	0.68	7.59E-12	5.30	+++++++	60	1.13E-02
12	HDL-TC	TC	-2.18	0.32	1.61E-11	-----	3	4.07E-01	-2.55	0.31	1.14E-16	5.15	-+-----	49	4.66E-02
13	HDL-LDL	HDL-C	-0.99	0.13	9.49E-15	-+-----+	65	3.77E-03	-1.08	0.13	1.93E-17	2.69	-+-----+	64	5.00E-03
14	TC-TG	TC	4.48	0.62	3.38E-13	+++++++	31	1.74E-01	4.91	0.61	9.22E-16	2.56	+++++++	0	4.38E-01
15	HDL-TC	HDL-C	-1.64	0.24	4.13E-12	-----	31	1.71E-01	-1.80	0.24	1.92E-14	2.33	-----	24	2.32E-01
16	LDL-TG	HDL-C	0.24	0.13	5.95E-02	+++++++	55	2.43E-02	0.68	0.12	4.91E-09	7.08	+++++++	44	7.45E-02
17	HDL-TC	LDL-C	0.05	0.35	8.75E-01	-+-----+	0	9.16E-01	-1.90	0.15	3.49E-38	37.40	-----	0	8.43E-01
18	HDL-LDL	TG	3.27	0.82	6.17E-05	+++++++	12	3.35E-01	6.82	0.74	3.57E-20	15.24	+++++++	0	8.15E-01
19	TC-TG	TG	-0.27	1.03	7.90E-01	---+---+	26	2.11E-01	3.98	0.94	2.25E-05	4.54	+++++++	22	2.48E-01
20	HDL-LDL	TG	0.29	0.88	7.43E-01	-+-----+	0	9.84E-01	2.54	0.80	1.49E-03	2.70	+++++++	0	9.77E-01
21	TC-TG	HDL-C	0.12	0.23	6.05E-01	-+---+?+	5	3.89E-01	-0.42	0.21	4.26E-02	1.15	-+---+?+	48	6.26E-02
22	HDL-LDL	TG	5.75	2.01	4.19E-03	+++++++?+	10	3.57E-01	8.49	1.91	8.67E-06	2.68	+++++++?+	0	4.46E-01
23	TC-TG	TC	5.01	0.44	2.51E-30	+++++++?+	66	7.39E-03	5.24	0.43	1.55E-33	3.21	+++++++?+	62	1.47E-02

**Supplementary Table 3.** (continue)

SNP info	Current Study			Prior Studies		
	Efficiency			Lead SNP	LD, %	Effect sign
ID	Str	N	A			
1	51	9	AP	rs1077514	0.4	??-?
2	27	6	AP	rs2479409	4.6	?++?
3	21	7	P	rs2131925	100	?---
4	115	9	P	rs629301	100	?--?
5	26	6	AP	rs629301	100	?--?
6	26	9	AP	rs4846914	100	-??+
7	38	9	AP	rs514230	94	?--?
8	34	9	AP	rs1367117	82.8	?++?
9	30	6	AP	rs1367117	82.8	?++?
10	21	7	AP	rs4299376	4.1	?++?
11	48	8	AP	rs4299376	4.1	?++?
12	91	8	AP	rs7570971	34.7	?++?
13	38	6	AP	rs12916	93.9	?++?
14	20	9	AP	rs12916	93.9	?++?
15	21	9	AP	rs3177928	96.6	?++?
16	53	8	AP	rs1564348	100	?++?
17	368	9	P	rs1564348	100	?++?
18	52	8	AP	rs4142995	13.8	-???
19	20	8	P	rs17145738	100	+??-
20	26	8	AP	rs4731702	100	+???
21	21	6	P	rs9987289	73.4	---?
22	45	6	AP	rs12678919	100	+??-
23	48	7	AP	rs12678919	100	+??-

**SNP info**

ID is a sequential single nucleotide polymorphism (SNP) number; Chr = chromosome; Position is position in base pairs; Locus denotes locus name as used in previous studies.

Gene is a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP was assigned; EA denotes minor allele used as an effect allele in an additive genetic model; EAF = EA frequency.

**Current Study**

Trait pair = a pair of lipid traits examined

Beta denotes effect size and direction of the genetic association; SE = standard error.

Direction shows the signs of associations in each of the included cohorts ordered as CHS, FHS\_C1, FHS\_C2, FHS\_C3, HRS, ARIC, CARDIA, MESA, and WHI, where “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects, respectively, and “?” indicates the lack of estimate.

$I^2$  is coefficient of heterogeneity in the meta-analysis; HetPVal is heterogeneity  $p$ -value in the meta-analysis.  
dlogP is the difference of the log-base-10-transformed  $p$ -values in the unconditional and conditional analyses.  
Str denotes the strength of antagonistic heterogeneity defined as the relative change of log-transformed  $p$ -values (%), i.e.,  
 $100 \times (\log_{10}(p_{cond}) - \log_{10}(p_{uncond})) / \log_{10}(p_{uncond})$ .  
Column N shows the number of cohorts in which antagonistic heterogeneity was replicated; Column A reports anterior (A) and posterior (P) antagonistic heterogeneity observed in our unconditional and conditional analyses, respectively.

### **Prior Studies**

Lead SNP is leading SNP identified in previous studies; LD = linkage disequilibrium between the lead SNPs and SNPs identified in the current study; Effect sign shows directions of genome-wide significant associations of the lead SNPs with HDL-C, LDL-C, TC, and TG reported in previous studies. Symbols “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects attained GW significance (i.e.,  $p \leq p_{GW}$ ), respectively, and “?” indicates associations, which did not attain GW significance level (i.e.,  $p > p_{GW}$ ).

**Supplementary Table 4. Extended table showing new genetic associations with lipid traits and the associations strongly affected by antagonistic genetic heterogeneity.**

SNP info								
ID	SNP	Chr	Position	Locus	Gene	Function	EA	EAF
1	rs4350231	1	62,922,660	ANGPTL3	DOCK7	intron	a	0.33
2	rs6544366	2	21,204,025	APOB		intergenic	t	0.23
3	rs780094	2	27,741,237	GCKR	GCKR	intron	t	0.42
4	rs780094	2	27,741,237	GCKR	GCKR	intron	t	0.42
5	rs10928512	2	135,451,302	RAB3GAP1	TMEM163	intron	g	0.47
6	rs7607980	2	165,551,201	COBLL1	COBLL1	missense	c	0.12
7	rs2394895	6	31,206,979	HLA		intergenic	c	0.26
8	rs2394895	6	31,206,979	HLA		intergenic	c	0.26
9	rs2394895	6	31,206,979	HLA		intergenic	c	0.26
10	rs9267531	6	31,636,742	HLA	CSNK2B,LY6G5B	intron, nearGene-5	g	0.10
11	rs9267531	6	31,636,742	HLA	CSNK2B,LY6G5B	intron, nearGene-5	g	0.10
12	rs17145738	7	72,982,874	MLXIPL	TBL2	nearGene-3	t	0.12
13	rs17145738	7	72,982,874	MLXIPL	TBL2	nearGene-3	t	0.12
14	rs13230111	7	130,437,124	KLF14	LOC105375508	intron	g	0.48
15	rs263	8	19,812,812	LPL	LPL	intron	t	0.18
16	rs3890182	9	107,647,655	ABCA1	ABCA1	intron	a	0.12
17	rs3890182	9	107,647,655	ABCA1	ABCA1	intron	a	0.12
18	rs651821	11	116,662,579	APOA1	APOA5	UTR-5	c	0.07
19	rs11216162	11	116,728,277	APOA1	SIK3	intron	a	0.18
20	rs11216162	11	116,728,277	APOA1	SIK3	intron	a	0.18
21	rs11216162	11	116,728,277	APOA1	SIK3	intron	a	0.18
22	rs7120963	11	116,830,261	APOA1	SIK3	intron	t	0.36
23	rs7120963	11	116,830,261	APOA1	SIK3	intron	t	0.36
24	rs7298565	12	109,937,534	MVK	UBE3B	missense	g	0.46
25	rs1109559	12	123,757,861	SBNO1	CDK2AP1	nearGene-5	g	0.31
26	rs1109559	12	123,757,861	SBNO1	CDK2AP1	nearGene-5	g	0.31
27	rs2038280	14	39,983,128	FBXO33	LOC105370460	intron	g	0.20
28	rs261332	15	58,727,325	LIPC	LIPC	intron	a	0.20
29	rs261332	15	58,727,325	LIPC	LIPC	intron	a	0.20
30	rs289715	16	57,008,508	CETP	CETP	intron	a	0.12
31	rs289715	16	57,008,508	CETP	CETP	intron	a	0.12
32	rs10468274	16	67,922,342	LCAT	NRN1L	intron	a	0.17
33	rs10468274	16	67,922,342	LCAT	NRN1L	intron	a	0.17
34	rs10438978	18	47,158,186	LIPG	LOC105372112	intron	t	0.17
35	rs10438978	18	47,158,186	LIPG	LOC105372112	intron	t	0.17



Supplementary Table 4. (continue)

SNP info	Current Study														
	Trait pair	Trait_1_unconditional							Trait_1_conditional						
ID	Trait pair	Trait_1	Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TG	HDL-C	-0.31	0.13	1.35E-02	-----+?	7	3.78E-01	-0.57	0.12	8.07E-07	6.09	-----	0	7.21E-01
2	HDL-TC	HDL-C	0.78	0.15	1.20E-07	+++++++?	0	7.87E-01	0.85	0.15	5.86E-09	1.31	+++++++?	0	7.66E-01
3	HDL-TG	HDL-C	0.00	0.12	9.83E-01	++++-----	13	3.26E-01	0.58	0.11	2.05E-07	6.68	+++++++?	0	5.69E-01
4	LDL-TC	LDL-C	0.92	0.28	1.12E-03	+++++++?	0	9.72E-01	-1.05	0.12	2.84E-19	15.60	-----	22	2.45E-01
5	HDL-LDL	LDL-C	1.55	0.28	3.59E-08	+++++++?	0	5.69E-01	1.65	0.28	3.12E-09	1.06	+++++++?	0	5.67E-01
6	TC-TG	TG	-5.09	0.91	2.27E-08	---+-----	41	9.48E-02	-4.96	0.87	1.19E-08	0.28	---+-----	45	6.94E-02
7	HDL-TG	HDL-C	-0.51	0.14	1.71E-04	-+-----	7	3.79E-01	-0.62	0.12	8.14E-07	2.32	-----	26	2.11E-01
8	LDL-TC	LDL-C	0.32	0.32	3.21E-01	++++-----	14	3.79E-01	0.72	0.13	5.09E-08	6.80	+++++++?	45	6.89E-02
9	LDL-TC	TC	-0.41	0.35	2.38E-01	++++-----	0	6.14E-01	-0.78	0.14	3.56E-08	6.82	-----	23	2.36E-01
10	HDL-TG	TG	-4.34	1.04	3.16E-05	-----+?	9	3.60E-01	-5.28	0.95	2.81E-08	3.05	-----+?	20	2.63E-01
11	LDL-TC	LDL-C	-0.49	0.46	2.88E-01	-+-----	22	2.45E-01	0.86	0.19	3.53E-06	4.91	+++++++?	35	1.40E-01
12	LDL-TC	LDL-C	0.22	0.43	6.04E-01	++++-----	39	1.06E-01	1.04	0.18	2.61E-09	8.36	+++++++?	0	9.42E-01
13	LDL-TC	TC	-1.03	0.46	2.55E-02	-----+?	33	1.52E-01	-1.20	0.19	2.55E-10	8.00	-----	0	9.57E-01
14	LDL-TG	TG	-2.83	0.67	2.29E-05	-----?	19	2.77E-01	-3.14	0.56	2.66E-08	2.94	-----?	2	4.13E-01
15	TC-TG	TC	0.77	0.39	4.86E-02	++++-----?	60	3.73E-02	1.88	0.38	5.22E-07	4.97	++++-----?	39	1.19E-01
16	LDL-TC	LDL-C	-0.83	0.42	4.97E-02	++++-----	36	1.30E-01	0.94	0.18	1.76E-07	5.45	++++-----	0	7.21E-01
17	LDL-TC	TC	-1.99	0.46	1.52E-05	-+-----	35	1.38E-01	-1.28	0.19	3.27E-11	5.67	-+-----	0	7.60E-01
18	LDL-TC	LDL-C	2.26	0.56	6.05E-05	++++-----	48	5.11E-02	-1.17	0.23	5.43E-07	2.05	-----	0	6.38E-01
19	HDL-TG	TG	2.29	0.87	8.84E-03	++++-----	0	8.20E-01	3.96	0.80	6.53E-07	4.13	++++-----	0	7.72E-01
20	LDL-TC	LDL-C	-0.18	0.36	6.25E-01	++++-----	0	4.36E-01	-1.11	0.15	4.53E-13	12.14	-----	0	7.13E-01
21	LDL-TC	TC	1.19	0.40	2.60E-03	++++-----	0	6.20E-01	1.30	0.17	8.27E-15	11.50	++++-----	0	8.70E-01
22	HDL-TG	HDL-C	0.24	0.13	5.95E-02	++++-----	55	2.43E-02	0.68	0.12	4.91E-09	7.08	++++-----	44	7.45E-02
23	LDL-TC	LDL-C	0.68	0.29	1.92E-02	++++-----	45	6.92E-02	-0.84	0.12	8.73E-12	9.34	-----	24	2.31E-01
24	TC-TG	TC	-1.61	0.30	1.10E-07	-----	0	8.29E-01	-1.62	0.29	2.55E-08	0.64	-----	0	8.19E-01
25	TC-TG	TC	1.71	0.33	1.82E-07	++++-----	0	7.04E-01	1.80	0.31	9.04E-09	1.30	++++-----	34	1.44E-01
26	HDL-LDL	HDL-C	0.54	0.13	3.78E-05	++++-----	0	7.11E-01	0.64	0.13	8.69E-07	1.64	++++-----	0	6.84E-01
27	TC-TG	TC	2.15	0.41	1.22E-07	++++?+++?	48	7.26E-02	2.20	0.39	1.32E-08	0.97	++++?+++?	39	1.34E-01
28	HDL-TG	TG	3.27	0.82	6.17E-05	++++-----	12	3.35E-01	6.82	0.74	3.57E-20	15.24	++++-----	0	8.15E-01
29	LDL-TC	LDL-C	0.05	0.35	8.75E-01	++++-----	0	9.16E-01	-1.90	0.15	3.49E-38	37.40	-----	0	8.43E-01
30	LDL-TC	LDL-C	-0.93	0.44	3.54E-02	-----	21	2.61E-01	-1.83	0.18	1.38E-23	21.41	-----	0	4.93E-01
31	LDL-TC	TC	1.22	0.48	1.17E-02	++++-----	30	1.82E-01	1.99	0.20	3.25E-23	20.56	++++-----	17	2.95E-01
32	LDL-TC	LDL-C	-0.05	0.37	8.90E-01	++++-----	0	5.17E-01	-0.89	0.16	1.02E-08	7.94	-+-----	0	5.90E-01
33	LDL-TC	TC	0.92	0.40	2.31E-02	++++-----	0	4.59E-01	1.04	0.17	8.71E-10	7.42	++++-----	0	5.28E-01
34	LDL-TC	LDL-C	-0.06	0.38	8.65E-01	-+-----?	0	5.65E-01	1.14	0.16	2.59E-13	12.52	++++-----?	0	6.35E-01
35	LDL-TC	TC	-1.69	0.41	3.76E-05	-----+?	0	7.41E-01	-1.36	0.17	8.28E-16	10.66	-----?	0	7.20E-01

Supplementary Table 4. (continue)

SNP info	Current Study														
	ID	Trait pair	Trait 2 conditional						Trait 2 conditional						
Trait 2			Beta	SE	P-value	Direction	I <sup>2</sup>	HetPVal	Beta	SE	P-value	dlogP	Direction	I <sup>2</sup>	HetPVal
1	HDL-TG	TG	-3.82	0.68	1.94E-08	-----	33	1.51E-01	-4.35	0.62	2.07E-12	3.97	-----	11	3.45E-01
2	HDL-TC	TC	-2.14	0.36	3.69E-09	-----+?	17	2.99E-01	-2.34	0.36	6.71E-11	1.74	-----+?	12	3.40E-01
3	HDL-TG	TG	7.72	0.68	3.96E-30	+++++++	44	7.55E-02	7.73	0.61	2.18E-36	6.26	+++++++	47	5.97E-02
4	LDL-TC	TC	2.32	0.31	3.29E-14	+++++++	0	9.46E-01	1.45	0.13	9.93E-30	15.52	+++++++	4	4.02E-01
5	HDL-LDL	HDL-C	0.34	0.12	4.71E-03	+++-----?	0	5.53E-01	0.42	0.12	5.36E-04	0.94	+++-----?	0	6.39E-01
6	TC-TG	TC	-0.03	0.45	9.56E-01	+++-----	0	7.90E-01	0.50	0.43	2.50E-01	0.58	+++-----	0	8.45E-01
7	HDL-TG	TG	-1.09	0.74	1.40E-01	+++-----	0	4.44E-01	-2.26	0.67	7.66E-04	2.26	-----	27	2.08E-01
8	LDL-TC	TC	-0.41	0.35	2.38E-01	+++-----	0	6.14E-01	-0.78	0.14	3.56E-08	6.82	-----	23	2.36E-01
9	LDL-TC	LDL-C	0.32	0.32	3.21E-01	++++-----	14	3.15E-01	0.72	0.13	5.09E-08	6.80	++++-----	45	6.89E-02
10	HDL-TG	HDL-C	-0.42	0.20	3.30E-02	---+-----	0	5.53E-01	-0.72	0.18	6.32E-05	2.72	---+-----	1	4.27E-01
11	LDL-TC	TC	-1.83	0.50	2.34E-04	---+-----	0	5.67E-01	-1.12	0.20	3.07E-08	3.88	-----	24	2.30E-01
12	LDL-TC	TC	-1.03	0.46	2.55E-02	-----+	33	1.52E-01	-1.20	0.19	2.55E-10	8.00	-----	0	9.57E-01
13	LDL-TC	LDL-C	0.22	0.43	6.04E-01	++++-----	39	1.06E-01	1.04	0.18	2.61E-09	8.36	++++-----	0	9.42E-01
14	LDL-TG	LDL-C	-0.13	0.28	6.39E-01	+++-----?	0	5.24E-01	0.00	0.28	9.90E-01	-0.19	+++-----?	0	5.42E-01
15	TC-TG	TG	-7.48	0.83	1.43E-19	-----?	22	2.56E-01	-7.91	0.79	9.10E-24	4.20	-----?	34	1.61E-01
16	LDL-TC	TC	-1.99	0.46	1.52E-05	+-----+	35	1.38E-01	-1.28	0.19	3.27E-11	5.67	+-----+	0	7.60E-01
17	LDL-TC	LDL-C	-0.83	0.42	4.97E-02	++-----+	36	1.30E-01	0.94	0.18	1.76E-07	5.45	++-----+	0	7.21E-01
18	LDL-TC	TC	4.48	0.62	3.38E-13	+++++++	31	1.74E-01	1.89	0.25	8.23E-14	0.61	+++++++	13	3.28E-01
19	HDL-TG	HDL-C	0.83	0.16	1.73E-07	+++++++	0	6.73E-01	1.01	0.15	5.05E-12	4.54	+++++++	0	6.89E-01
20	LDL-TC	TC	1.19	0.40	2.60E-03	++++-----	0	6.20E-01	1.30	0.17	8.27E-15	11.50	++++-----	0	8.70E-01
21	LDL-TC	LDL-C	-0.18	0.36	6.25E-01	+++-----	0	4.36E-01	-1.11	0.15	4.53E-13	12.14	-----	0	7.13E-01
22	HDL-TG	TG	5.46	0.72	2.65E-14	+++++++	42	8.85E-02	6.20	0.65	1.82E-21	7.16	+++++++	0	5.04E-01
23	LDL-TC	TC	1.94	0.32	8.27E-10	++++-----	13	3.28E-01	1.15	0.13	4.55E-18	8.26	++++-----	0	5.21E-01
24	TC-TG	TG	-0.22	0.65	7.35E-01	-----+	0	9.84E-01	0.77	0.62	2.16E-01	0.53	-----+	0	1.00E+00
25	TC-TG	TG	-0.37	0.70	6.04E-01	---+-----	0	6.33E-01	-1.50	0.68	2.63E-02	1.36	---+-----	20	2.61E-01
26	HDL-LDL	LDL-C	1.20	0.30	6.50E-05	++++-----	43	8.12E-02	1.37	0.30	3.55E-06	1.26	++++-----	48	5.24E-02
27	TC-TG	TG	-0.65	0.89	4.62E-01	---+?---?	0	7.01E-01	-1.94	0.85	2.23E-02	1.32	---+?---?	0	9.82E-01
28	HDL-TG	HDL-C	1.58	0.15	2.73E-25	+++++++	34	1.49E-01	1.81	0.14	3.71E-38	12.87	+++++++	35	1.35E-01
29	LDL-TC	TC	2.39	0.38	2.31E-10	++++-----	0	7.95E-01	2.27	0.16	8.12E-46	35.45	++++-----	0	7.39E-01
30	LDL-TC	TC	1.22	0.48	1.17E-02	---+-----	30	1.82E-01	1.99	0.20	3.25E-23	20.56	---+-----	17	2.95E-01
31	LDL-TC	LDL-C	-0.93	0.44	3.54E-02	---+-----	21	2.61E-01	-1.83	0.18	1.38E-23	21.41	---+-----	0	4.93E-01
32	LDL-TC	TC	0.92	0.40	2.31E-02	++++-----	0	4.59E-01	1.04	0.17	8.71E-10	7.42	++++-----	0	5.28E-01
33	LDL-TC	LDL-C	-0.05	0.37	8.90E-01	+++-----	0	5.17E-01	-0.89	0.16	1.02E-08	7.94	+++-----	0	5.90E-01
34	LDL-TC	TC	-1.69	0.41	3.76E-05	-----+?	0	7.41E-01	-1.36	0.17	8.28E-16	10.66	-----+?	0	7.20E-01
35	LDL-TC	LDL-C	-0.06	0.38	8.65E-01	---+-----?	0	5.65E-01	1.14	0.16	2.59E-13	12.52	---+-----?	0	6.35E-01

**Supplementary Table 4.** (continue)

SNP info	Current Study			Prior Studies		
	Efficiency			Lead SNP	LD, %	Effect sign
ID	Str	N	A			
1	326	9	AP	rs2131925	97.8	?--
2	19	6	AP	rs1367117	10.7	?++?
3	88144	7	P	rs1260326	92	??++
4	529	9	P	rs1260326	92	??++
5	14	7	AP	rs7570971	16	??+?
6	4	6	P	rs12328675	96.2	+???
7	62	9	AP	rs3177928	5.7	?++?
8	1378	9	AP	rs3177928	5.7	?++?
9	1093	9	AP	rs3177928	5.7	?++?
10	68	7	AP	rs3177928	2.1	?++?
11	908	9	P	rs3177928	2.1	?++?
12	3813	8	AP	rs17145738	100	+??-
13	502	8	AP	rs17145738	100	+??-
14	63	5	P	rs4731702	100	+???
15	378	7	AP	rs12678919	33.8	+??-
16	418	6	P	rs1883025	13.8	-?-?
17	118	6	P	rs1883025	13.8	-?-?
18	49	9	P	rs964184	51.9	+---
19	201	9	AP	rs964184	9.9	+---
20	5943	9	AP	rs964184	9.9	+---
21	445	9	AP	rs964184	9.9	+---
22	578	8	AP	rs964184	25.2	+---
23	544	9	P	rs964184	25.2	+---
24	9	8	P	rs7134594	96	-???
25	19	7	AP	rs4759375	14.1	+???
26	37	8	AP	rs4759375	14.1	+???
27	14	7	AP			????
28	362	8	AP	rs1532085	0.3	+?++
29	64325	9	P	rs1532085	0.3	+?++
30	1475	8	AP	rs3764261	17.5	+++-
31	1065	8	AP	rs3764261	17.5	+++-
32	15756	8	AP	rs16942887	69.1	+???
33	454	8	AP	rs16942887	69.1	+???
34	19932	8	P	rs7241918	96.4	-?-?
35	241	8	P	rs7241918	96.4	-?-?

**SNP info**

ID is a sequential single nucleotide polymorphism (SNP) number; Chr = chromosome; Position is position in base pairs; Locus denotes locus name as used in previous studies.

Gene is a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP was assigned; EA denotes minor allele used as an effect allele in an additive genetic model; EAF = EA frequency.

### **Current Study**

Trait pair = a pair of lipid traits examined

Beta denotes effect size and direction of the genetic association; SE = standard error.

Direction shows the signs of associations in each of the included cohorts ordered as CHS, FHS\_C1, FHS\_C2, FHS\_C3, HRS, ARIC, CARDIA, MESA, and WHI, where “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects, respectively, and “?” indicates the lack of estimate.

$I^2$  is coefficient of heterogeneity in the meta-analysis; HetPVal is heterogeneity  $p$ -value in the meta-analysis.

dlogP is the difference of the log-base-10-transformed  $p$ -values in the unconditional and conditional analyses.

Str denotes the strength of antagonistic heterogeneity defined as the relative change of log-transformed  $p$ -values (%), i.e.,  $100 \times (\log_{10}(p_{cond}) - \log_{10}(p_{uncond})) / \log_{10}(p_{uncond})$ .

Column N shows the number of cohorts in which antagonistic heterogeneity was replicated; Column A reports anterior (A) and posterior (P) antagonistic heterogeneity observed in our unconditional and conditional analyses, respectively.

### **Prior Studies**

Lead SNP is leading SNP identified in previous studies; LD = linkage disequilibrium between the lead SNPs and SNPs identified in the current study; Effect sign shows directions of genome-wide significant associations of the lead SNPs with HDL-C, LDL-C, TC, and TG reported in previous studies. Symbols “+” and “-” denote positive (increase) and negative (decrease) signs of statistical effects attained GW significance (i.e.,  $p \leq p_{GW}$ ), respectively, and “?” indicates associations, which did not attain GW significance level (i.e.,  $p > p_{GW}$ ).